Amanta Healthcare Limited submitted a regulatory filing under SEBI Listing Regulations Regulation 30, enclosing a press release announcing unaudited financial results for the quarter ended June 30, 2026 (Q1FY27).

Financial Performance Highlights

Revenue Performance:

  • Q1FY27 revenue: ₹68.8 crore
  • Year-over-year growth: 5.4%
  • Growth drivers: Improved product mix and better price realizations
  • Achieved on existing capacity base

Operational Performance:

  • Q1FY27 EBITDA: ₹15.2 crore (includes other income)
  • Q1FY26 EBITDA: ₹15.9 crore
  • Q1FY27 EBITDA margin: 22%
  • Q1FY26 EBITDA margin: 24%
  • Margin decline: 200 basis points
  • Reasons for margin pressure: Higher raw material costs, higher employee costs, and higher other operating costs

Profitability:

  • Q1FY27 PAT: ₹3.3 crore
  • Q1FY26 PAT: ₹3.5 crore
  • Year-over-year decline: 5.6%
  • PAT margin: 4.8%
  • Primary reason for decline: Higher finance costs due to new Solar Term Loan

Capacity Expansion and Strategic Initiatives

Steriport Plant:

  • Expected commissioning: Q2FY27

SVP Expansion:

  • Targeted completion: Q4FY27

Solar Power Plant:

  • Captive solar power project mentioned as supporting cost efficiencies

Expected Benefits:

  • Material enhancement of manufacturing capacity
  • Improved cost efficiency
  • Enhanced operating leverage
  • Expected to drive growth over coming years

Management Commentary

Bhavesh Patel, Chairman & Managing Director, commented on the quarterly performance:

  • Q1FY27 represented a period of steady performance
  • Revenue growth driven by improved product mix and better price realizations
  • EBITDA margins maintained at 22% despite cost pressures
  • PAT impacted by higher finance costs
  • Exciting growth opportunities expected in coming quarters from capacity expansion
  • SteriPort facility commissioning expected by Q2FY27
  • SVP expansion targeted for Q4FY27
  • Solar power project to support cost efficiencies and strengthen operating profile
  • Confidence in building greater scale, enhancing profitability, and unlocking sustainable growth opportunities across domestic and export markets

Company Background

Amanta Healthcare Limited is a pharmaceutical company engaged in development, manufacturing, and marketing of sterile liquid products including both large and small volume parenteral (LVPs and SVPs). The company uses advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies, serving six therapeutic segments with products including IV fluids, diluents, ophthalmic and respiratory care, and irrigation solutions. Packaging includes a wide range of closure systems and container volumes from 2 ml to 1000 ml.